{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:25:59Z","timestamp":1758223559237,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background\/Objectives<\/jats:title>\n            <jats:p>To study the associations of VA and intermediate age-related macular degeneration (iAMD) subclassifications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Subjects\/Methods<\/jats:title>\n            <jats:p>This is the analysis of baseline data of a multicentre study on patients with iAMD in at least one eye. The subclassifications of iAMD were classified as: (i) iAMD with no evidence of incomplete retinal pigment epithelial and outer retinal atrophy (iRORA) or subretinal drusenoid deposits (SDD); (ii) iAMD with SDD with no iRORA; (iii) iAMD with iRORA with no SDD and (iv) iAMD with iRORA and SDD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>983 eyes from 805 patients with iAMD were analysed. The mean age was 75.8 years (SD 7.9), with 35.0% (282) male. Eyes with iRORA with SDD had lower VA relative to eyes with no iRORA and no SDD (OR\u2009=\u20090.98 [95% CI 0.96, 0.998]; <jats:italic>P<\/jats:italic>\u2009=\u20090.03). The VA in the better seeing eye was significantly higher than in the worse seeing eye. Increased age (sex adjusted OR, 1.07, 95% CI 1.05\u20131.09; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and female gender (age adjusted OR, 0.75, 95% CI 0.56\u20131.01; <jats:italic>P<\/jats:italic>\u2009=\u20090.057) were associated with SDD. Eyes with nAMD in the fellow eye had reduced odds of iRORA in the study eye (adjusted OR\u2009=\u20090.60, 95% CI 0.40\u20130.91; <jats:italic>P<\/jats:italic>\u2009=\u20090.015). Eyes with GA had increased odds of iRORA in the study eye (adjusted OR\u2009=\u20093.30, 95% CI 2.00\u20135.45; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Baseline age, presence of SDD and\/or iRORA and fellow eye status need to be considered in future clinical trials evaluating preventive or treatment options for iAMD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41433-025-03895-y","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T16:10:33Z","timestamp":1752941433000},"page":"2655-2663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Visual acuity in various phenotypes of intermediate age related macular degeneration (AMD) in a multicentre cohort study in Europe- INTERCEPT-AMD report 1"],"prefix":"10.1038","volume":"39","author":[{"given":"Sarega","family":"Gurudas","sequence":"first","affiliation":[]},{"given":"In\u00eas","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Jean-Fran\u00e7ois","family":"Girmens","sequence":"additional","affiliation":[]},{"given":"Yara","family":"Lechanteur","sequence":"additional","affiliation":[]},{"given":"Maria Cristina","family":"Parravano","sequence":"additional","affiliation":[]},{"given":"Lieselotte","family":"Berger","sequence":"additional","affiliation":[]},{"given":"Hansj\u00fcrgen","family":"Agostini","sequence":"additional","affiliation":[]},{"given":"Sandra","family":"Barr\u00e3o","sequence":"additional","affiliation":[]},{"given":"Evangelos","family":"Tsiroukis","sequence":"additional","affiliation":[]},{"given":"Jordi","family":"Mon\u00e9s","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Sararols","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-0833","authenticated-orcid":false,"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Hendrik","family":"Scholl","sequence":"additional","affiliation":[]},{"given":"Albrecht","family":"Lommatzsch","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-1539","authenticated-orcid":false,"given":"Boris","family":"Stanzel","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-9967","authenticated-orcid":false,"given":"Stela","family":"Vujosevic","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":false,"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[]},{"name":"On behalf of the INTERCEPT-AMD Study Group","sequence":"additional","affiliation":[]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[]},{"given":"Hendrik P. N.","family":"Scholl","sequence":"additional","affiliation":[]},{"given":"Yannick","family":"Liermann","sequence":"additional","affiliation":[]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[]},{"given":"Emily","family":"Fletcher","sequence":"additional","affiliation":[]},{"given":"Savita","family":"Madhusudhan","sequence":"additional","affiliation":[]},{"given":"Lyubomyr","family":"Lytvynchuk","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[]},{"given":"Nicole","family":"Eter","sequence":"additional","affiliation":[]},{"given":"Stefano","family":"de Cilla","sequence":"additional","affiliation":[]},{"given":"Michel","family":"Weber","sequence":"additional","affiliation":[]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"3895_CR1","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study","year":"2021","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e144\u2013e160. https:\/\/doi.org\/10.1016\/S2214-109X(20)30489-7.","journal-title":"Lancet Glob Health"},{"key":"3895_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris 3rd","year":"2013","unstructured":"Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844\u201351.","journal-title":"Ophthalmology"},{"key":"3895_CR3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1001\/jamaophthalmol.2020.0824","volume":"138","author":"S Vitale","year":"2020","unstructured":"Vitale S, Agr\u00f3n E, Clemons TE, Keenan TDL, Domalpally A, Danis RP, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmol. 2020;138:610\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"3895_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.survophthal.2008.12.003","volume":"54","author":"K Neelam","year":"2009","unstructured":"Neelam K, Nolan J, Chakravarthy U, Beatty S. Psychophysical function in age-related maculopathy. Surv Ophthalmol. 2009;54:167\u2013210.","journal-title":"Surv Ophthalmol"},{"key":"3895_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/IAE.0000000000001002","volume":"36","author":"A Chandramohan","year":"2016","unstructured":"Chandramohan A, Stinnett SS, Petrowski JT, Schuman SG, Toth CA, Cousins SW, et al. Visual function measures in early and intermediate age-related macular degeneration. Retin (Philos, Pa). 2016;36:1021\u201331.","journal-title":"Retin (Philos, Pa)"},{"key":"3895_CR6","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.oret.2022.05.002","volume":"6","author":"JR Abraham","year":"2022","unstructured":"Abraham JR, Jaffe GJ, Kaiser PK, Chiu SJ, Loo J, Farsiu S, et al. Impact of baseline quantitative OCT features on response to risuteganib for the treatment of dry age-related macular degeneration: the importance of outer retinal integrity. Ophthalmol Retin. 2022;6:1019\u201327.","journal-title":"Ophthalmol Retin"},{"key":"3895_CR7","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1167\/iovs.17-22339","volume":"58","author":"K Csaky","year":"2018","unstructured":"Csaky K, Ferris F, Chew EY, Nair P, Cheetham JK, Duncan JL. Report From the NEI\/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases. Invest Ophthalmol Vis Sci. 2018;58:3456\u201363.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3895_CR8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.oret.2020.01.012","volume":"4","author":"U Chakravarthy","year":"2020","unstructured":"Chakravarthy U, Bailey CC, Scanlon PH, McKibbin M, Khan RS, Mahmood S, et al. Progression from early\/intermediate to advanced forms of age-related macular degeneration in a large UK cohort: rates and risk factors. Ophthalmol Retin. 2020;4:662\u201372.","journal-title":"Ophthalmol Retin"},{"key":"3895_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ophtha.2018.09.015","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Wu Z, Hodgson LAB, Caruso E, Brassington KH, Tindill N, et al. Laser intervention in early stages of age-related macular degeneration study group. subthreshold nanosecond laser intervention in age-related macular degeneration: the LEAD randomized controlled clinical trial. Ophthalmology. 2019;126:829\u201338.","journal-title":"Ophthalmology"},{"key":"3895_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/IAE.0000000000003980","volume":"44","author":"D Boyer","year":"2024","unstructured":"Boyer D, Hu A, Warrow D, Xavier S, Gonzalez V, Lad E, et al. LIGHTSITE III: 13-month efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (dry) age-related macular degeneration using the lumithera valeda light delivery system. Retina. 2024;44:487\u201397.","journal-title":"Retina"},{"key":"3895_CR11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.survophthal.2018.05.005","volume":"63","author":"RF Spaide","year":"2018","unstructured":"Spaide RF, Ooto S, Curcio CA. Subretinal drusenoid deposits AKA pseudodrusen. Surv Ophthalmol. 2018;63:782\u2013815.","journal-title":"Surv Ophthalmol"},{"key":"3895_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.survophthal.2016.02.005","volume":"61","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Bird A, Nitiahpapand R, Nicholson L, Hykin P, Chatziralli I. Moorfields UCL AMD consortium. perspectives on reticular pseudodrusen in age-related macular degeneration. Surv Ophthalmol. 2016;61:521\u201337.","journal-title":"Surv Ophthalmol"},{"key":"3895_CR13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ophtha.2019.09.035","volume":"127","author":"RH Guymer","year":"2020","unstructured":"Guymer RH, Rosenfeld PJ, Curcio CA, Holz FG, Staurenghi G, Freund KB, et al. Incomplete retinal pigment epithelial and outer retinal atrophy in age-related macular degeneration: classification of atrophy meeting report 4. Ophthalmology. 2020;127:394\u2013409.","journal-title":"Ophthalmology"},{"key":"3895_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1159\/000517881","volume":"244","author":"S Schmitz-Valckenberg","year":"2021","unstructured":"Schmitz-Valckenberg S, Braun MD, Thiele S, Ferrara D, Honigberg L, Gao SS, et al. Conversion from intermediate age-related macular degeneration to geographic atrophy in a proxima B subcohort using a multimodal approach. Ophthalmologica. 2021;244:523\u201334.","journal-title":"Ophthalmologica"},{"key":"3895_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. ConsEnsus Definition For Atrophy Associated With Age-related Macular Degeneration on OCT: classification of atrophy report 3. Ophthalmology. 2018;125:537\u201348.","journal-title":"Ophthalmology"},{"key":"3895_CR16","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41433-021-01488-z","volume":"36","author":"MK Grewal","year":"2022","unstructured":"Grewal MK, Chandra S, Gurudas S, Rasheed R, Sen P, Menon D, et al. Functional clinical endpoints and their correlations in eyes with AMD with and without subretinal drusenoid deposits-a pilot study. Eye (Lond). 2022;36:398\u2013406.","journal-title":"Eye (Lond)"},{"key":"3895_CR17","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.3390\/jcm9092973","volume":"9","author":"MC Savastano","year":"2020","unstructured":"Savastano MC, Falsini B, Cozzupoli GM, Savastano A, Gambini G, De Vico U, et al. Retinal pigment epithelial and outer retinal atrophy in age-related macular degeneration: correlation with macular function. J Clin Med. 2020;9:2973.","journal-title":"J Clin Med"},{"key":"3895_CR18","doi-asserted-by":"publisher","unstructured":"Royston P, Sauerbrei W. Multivariable Model-Building: A Practical Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables. Hoboken: John Wiley & Sons, 2008. https:\/\/doi.org\/10.1002\/9780470770771.","DOI":"10.1002\/9780470770771"},{"key":"3895_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3928\/23258160-20210528-05","volume":"52","author":"DS Boyer","year":"2021","unstructured":"Boyer DS, Gonzalez VH, Kunimoto DY, Maturi RK, Roe RH, Singer MA, et al. Safety and efficacy of intravitreal risuteganib for non-exudative AMD: a multicenter, phase 2a, randomized, clinical trial. Ophthalmic Surg Lasers Imaging Retin. 2021;52:327\u201335.","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"3895_CR20","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","unstructured":"Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417\u201336.","journal-title":"Arch Ophthalmol"},{"key":"3895_CR21","doi-asserted-by":"crossref","unstructured":"REDS2 Research Group, Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, et al. The Age-related Eye Disease Study 2 (AREDS2) Study Design and Baseline Characteristics (AREDS2 Report Number 1) Ophthalmology. 2012;119:2282-9.","DOI":"10.1016\/j.ophtha.2012.05.027"},{"key":"3895_CR22","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1007\/s40123-024-01030-w","volume":"13","author":"E Borrelli","year":"2024","unstructured":"Borrelli E, Coco G, Pellegrini M, Mura M, Ciarmatori N, Scorcia V, et al. Safety, tolerability, and short-term efficacy of low-level light therapy for dry age-related macular degeneration. Ophthalmol Ther. 2024;13:2855\u201368.","journal-title":"Ophthalmol Ther"},{"key":"3895_CR23","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.ophtha.2011.04.029","volume":"118","author":"JM Seddon","year":"2011","unstructured":"Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology. 2011;118:2203\u201311.","journal-title":"Ophthalmology"},{"key":"3895_CR24","doi-asserted-by":"publisher","first-page":"6743","DOI":"10.1167\/iovs.10-6723","volume":"52","author":"RR Pappuru","year":"2011","unstructured":"Pappuru RR, Ouyang Y, Nittala MG, Hemmati HD, Keane PA, Walsh AC, et al. Relationship between outer retinal thickness substructures and visual acuity in eyes with dry age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:6743\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3895_CR25","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1167\/iovs.18-24106","volume":"59","author":"U Schmidt-Erfurth","year":"2018","unstructured":"Schmidt-Erfurth U, Waldstein SM, Klimscha S, Sadeghipour A, Hu X, Gerendas BS, et al. Prediction of individual disease conversion in early AMD using artificial intelligence. Invest Ophthalmol Vis Sci. 2018;59:3199\u2013208.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3895_CR26","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.2013.4997","volume":"309","author":"Age-Related Eye Disease Study 2 Research Group","year":"2013","unstructured":"Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309:2005\u201315.","journal-title":"JAMA"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03895-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03895-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03895-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:21:33Z","timestamp":1758190893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03895-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3895"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03895-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS reported receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi. SS is the Editor-in-Chief of EYE.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}